The possibility of an oral dosing is very exciting
Post# of 72440
(Total Views: 276)
Posted On: 02/10/2017 2:32:14 PM
The possibility of an oral dosing is very exciting. The high bioavailability in animal testing is a good starting point. K's short half-life makes it possible to dose the patients multiple times per day safely.
"With regards to secondary endpoints, it was determined that Kevetrin has a relatively short apparent biological half-life (less than 2 hr) in plasma. Plasma half-life (T1/2) clearance (CL) and volume of distribution (Vd) suggest that drug elimination predominantly involves hepatic mechanisms and Kevetrin undergoes rapid extensive distribution from systemic circulation into tissues. PK data, as measured by AUC and Cmax levels, further revealed that Kevetrin exhibited a dose-dependent response, has as stated a relatively short half-life (approximately 2 hours) and clears the body within one day – on average between 8 and 10 hours – though the drug can remain in the body up to approximately 24 hours, depending upon individual patient variations."
http://www.cellceutix.com/press-release-2/201...=half-life
"With regards to secondary endpoints, it was determined that Kevetrin has a relatively short apparent biological half-life (less than 2 hr) in plasma. Plasma half-life (T1/2) clearance (CL) and volume of distribution (Vd) suggest that drug elimination predominantly involves hepatic mechanisms and Kevetrin undergoes rapid extensive distribution from systemic circulation into tissues. PK data, as measured by AUC and Cmax levels, further revealed that Kevetrin exhibited a dose-dependent response, has as stated a relatively short half-life (approximately 2 hours) and clears the body within one day – on average between 8 and 10 hours – though the drug can remain in the body up to approximately 24 hours, depending upon individual patient variations."
http://www.cellceutix.com/press-release-2/201...=half-life
(8)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼